The new data presented by Novartis at ECTRIMS 2022 highlighted ... slow down the progression of the disease. Kesimpta is such a drug, taken as an injection under the skin once a month.

Adults with relapsing MS rated the Sensoready pen, an autoinjector used to self-administer Kesimpta, for ease of use and ...

Kesimpta is a brand-name subcutaneous injection prescribed for certain forms of multiple sclerosis (MS). Kesimpta begins working right away, but it may take some time for you to notice relief in ...

Novartis’ performance in the fourth quarter was impressive, driven by strong growth in Entresto, Kesimpta and Kisqali. The guidance for 2025 was encouraging, indicating strong momentum across ...

Novartis (NOVN.S), opens new tab on Friday posted adjusted net income well above analyst estimates as sales of established heart failure drug Entresto and newer multiple sclerosis drug Kesimpta ...

Kesimpta, Kisqali, Cosentyx and Leqvio. The top line beat the Zacks Consensus Estimate of $12.97 billion. Shares are up in response to the quarterly results. Shares of Novartis have risen 1.3% in ...